Search

Your search keyword '"Etravirine -- Research"' showing total 4 results
Start Over Descriptor "Etravirine -- Research" Topic nucleosides
4 results on '"Etravirine -- Research"'

1. Merck Announces Presentation of Phase 2b Results for Investigational HIV-1 Therapy Islatravir (MK-8591) at IAS 2019

Subjects
Merck & Company Inc. -- Product development -- Planning, Clinical trials, Efavirenz -- Research -- Product development -- Planning, Rifapentine -- Research -- Product development -- Planning, Oxcarbazepine -- Research, Enzalutamide -- Research, Rifabutin -- Research -- Product development -- Planning, DNA polymerases, Etravirine -- Research, HIV -- Research, Pharmaceutical industry -- Product development -- Planning, Nucleosides, Company business planning, Business, Business, international, Delstrigo (Medication), Pifeltro (Medication)
Abstract

New Findings from Study Evaluating Islatravir in Combination with Doravirine versus DELSTRIGO[TM] (doravirine 100 mg/3TC 300 mg/tenofovir disoproxil fumarate 300 mg) Company Plans to Initiate Phase 3 Trials KENILWORTH, N.J. [...]

Published
2019

2. Merck Highlights Commitment to HIV Research with Presentations for Investigational Anti-HIV Agent MK-8591 at IAS 2019

Subjects
Merck Research Laboratories, Merck & Company Inc., Efavirenz -- Research, Rifapentine -- Research, Oxcarbazepine -- Research, Enzalutamide -- Research, Rifabutin -- Research, Etravirine -- Research, HIV -- Research, Pharmaceutical industry, International relief -- United States, Vice presidents (Organizations), Conferences and conventions, AIDS (Disease), Nucleosides, DNA polymerases, General interest, News, opinion and commentary, Pifeltro (Medication)
Abstract

KENILWORTH: Merck has issued the following press release: Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the results from studies evaluating MK-8591, an [...]

Published
2019

3. Merck Highlights Commitment to HIV Research with Presentations for Investigational Anti-HIV Agent MK-8591 at IAS 2019

Subjects
Merck & Company Inc., Efavirenz -- Research, Rifapentine -- Research, Oxcarbazepine -- Research, Enzalutamide -- Research, Rifabutin -- Research, Etravirine -- Research, HIV -- Research, Pharmaceutical industry, International relief -- United States, Vice presidents (Organizations), Conferences and conventions, AIDS (Disease), Nucleosides, DNA polymerases, Business, Business, international, Pifeltro (Medication)
Abstract

Data Include Week 48 Results from Phase 2B Study Evaluating MK-8591 in Combination with Doravirine KENILWORTH, N.J. -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, [...]

Published
2019

4. Studies from Assistance Publique-Hopitaux de Paris Yield New Information about HIV/AIDS (Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected ...)

Subjects
HIV patients, Raltegravir -- Research, HIV infections -- Research, Etravirine -- Research, HIV -- Research, Medical research, Antiretroviral agents, AIDS (Disease), Immune system, Nucleosides, Health
Abstract

2019 JUL 15 (NewsRx) -- By a News Reporter-Staff News Editor at AIDS Weekly -- Investigators discuss new findings in Immune System Diseases and Conditions - HIV/AIDS. According to news [...]

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results